Rapid translocation of P-selectin (GMP-140) from cytoplasmic granules to the cell membrane ofendothelial cells promotes adhesive interactions with neutrophils which, when activated, damage the endothelium. The role ofP-selectin in lung vascular endothelial injury in rats after systemic activation of complement by intravenous infusion of cobra venom factor has been assessed. Within 5-10 min after cobra venom factor infusion, the pulmonary vasculature demonstrated immunohistochemical expression of an epitope that reacts with anti-human P-selectin. Monoclonal antibody to human P-selectin blocked in vitro adherence of rat or human platelets (activated with thrombin) to neutrophils and was demonstrated to react with thrombin-activated rat platelets. The antibody did not react with rat neutrophils. In vivo, the antibody had strongly protective effects against cobra venom factor-induced pulmonary vascular injury as determined by permeability changes and hemorrhage. In parallel, lung myeloperoxidase content was greatly reduced and, by transmission electron microscopy, there was markedly diminished adherence of neutrophils to the pulmonary vascular endothelium and much diminished injury ofendothelial cells, as defined by hemorrhage. These data indicate that anti-human P-selectin reacts with a pulmonary vascular antigen in rats and that this antigen is essential for the full expression of lung injury. (J. Clin. Invest. 1992Invest. . 90:1600Invest. -1607
Introduction
Neutrophils are key participants in the development of tissue injury in a variety of acute inflammatory diseases. It has recently been proposed that neutrophil recruitment to sites of inflammation occurs in several discrete steps involving: (a) rolling of the cells on the activated endothelium of the blood vessel wall; (b) activation of neutrophils; (c) firm adhesion of neutrophils to the endothelium; and (d) migration of neutro-phils into the surrounding tissue (1) (2) (3) (4) (5) (6) . This process involves multiple cell adhesion molecules expressed on the surfaces of neutrophils and endothelial cells. Rolling of leukocytes is believed to be mediated by members of the selectin family, L-selectin (LECAM-1, LAM-1, expressed on the neutrophil, and E-selectin (ELAM-1) and P-selectin (GMP-140, PADGEM) expressed on the endothelial cell (5) (6) (7) (8) (9) . Direct experimental evidence has been obtained for the roles of L-selectin (10) (11) (12) (13) (14) and E-selectin ( 15 ) in development of the inflammatory response in vivo. Firm adhesion and extravascular migration of neutrophils appears to require engagement of the neutrophil (32 integrins, LFA-l (CDl la/CD 1 8) and Mac-l (CDl lb/CD 1 8) , which bind to their counter ligand, intercellular adhesion model (ICAM-1,2) on endothelial cells (16) (17) (18) (19) (20) (21) (22) . There is direct evidence for the role of (32 integrins and ICAM-1,2 in the in vivo development of the inflammatory response (16) (17) (18) (19) (20) 23 ) . Indeed, the key role of (32 integrins has been shown in patients with a defect in the common subunit of the (32 integrins (CD18), in which case there is a profound inability to recruit neutrophils to inflammatory sites, the outcome of which is development of uncontained bacterial infections (23) .
Although in vitro studies have implicated P-selectin in mediating the rolling of leukocytes on activated endothelium (1) (2) (3) (4) (5) (6) (7) (8) (9) 24) , its role in the inflammatory response in vivo has not yet been demonstrated. P-selectin is stored in intracellular granules in endothelial cells (and platelets) and can be rapidly mobilized to the surface within minutes of activation of endothelial cells by thrombin, histamine, and oxygen radicals or peroxides (25) (26) (27) . The current studies were designed to investigate the possible role of P-selectin in acute lung injury due to systemic complement activation produced by vascular infusion into rats of the cobra venom factor (CVF).' Injury in this model develops rapidly and is known to be dependent on toxic oxygen products generated from neutrophils (28) . The following studies provide the first direct in vivo evidence that a rat epitope reactive with anti-human P-selectin is required for the full development of tissue injury during the acute inflammatory response in lung.
Methods
Antibodies to P-selectin. RBF/DnJ mice were immunized once with freshly isolated thrombin-activated human platelets and twice with "outdated platelets" (> 8 d old) which were further purified by differ-ential centrifugation. The mice were then twice immunized with partially purified human P-selectin. A hybridoma clone producing an IgG, antibody that blocked adhesion ofthrombin-activated human platelets to human neutrophils was the source ofa monoclonal antibody termed PB 1.3. Another antibody was termed PNB1.6. This antibody was obtained from a mouse immunized three times with thrombin-activated platelets. For analysis in immunoblotting, intact platelets were boiled in nonreducing SDS-PAGE sample buffer and subjected to electrophoresis in an 8-16% gel gradient, and then transferred to nitrocellulose. The blot was treated with 1% BSA in PBS and then incubated with appropriate antibody. The blot was washed, incubated with goat antimouse Ig conjugated with alkaline phosphatase, and then visualized with bromochloroindolyl phosphate/nitroblue tetrazolium. For the assay for P-selectin-mediated adhesion ofthrombin-activated platelets to human neutrophils, the fluid phase assay was used as recently described (29) , with the exception that, before additional ofisolated human neutrophils, the thrombin-activated platelets were incubated at room temperature for 20 min with various concentrations of the PB 1.3 and PNB1.6 antibodies.
Flow cytometric analysis ofbinding ofanti-P-selectin to rat platelets. Rat platelets were isolated by the method previously described for the isolation of human platelets ( 30, 31 ) . For activation with thrombin, the isolated platelets at a concentration of 5 x 108/ml were incubated for 20 min at room temperature without stirring with human thrombin (Sigma Chemical Co., St. Louis, MO) at 0.25 U/ml in the presence of 4 mM Ca". At the end ofthe incubation period, EDTA at a final concentration of 10 mM was added and the cell sample was centrifuged. The activated rat platelets were washed once in TyrodeHepes buffer, pH 7.2, containing 10 mM EDTA, and then resuspended to a concentration of 2 x 108/ml. A second aliquot of the same rat platelets was not activated with thrombin and the platelets were suspended in the same buffer at the same concentration. Platelets (0.15 ml), either thrombin activated or nonactivated, were incubated for 15 min at room temperature with buffer, anti-human P-selectin (PB 1.3), or with an isotype matched murine monoclonal antibody, antipenicillin, which was obtained from Calbiochem Corp. (La Jolla, CA). All antibody concentrations were at 33 ug/ml. All incubations were also done in the presence of 10% normal rat serum. The platelets were washed once and then incubated for 10 min with R-phycoerythrinconjugated goat anti-mouse IgG, (Southern Biotechnology Associates, Inc., Birmingham, AL) at a concentration of 1 gg/ml in the same buffer. Finally, the platelets were pelleted and then resuspended in 1 ml and subjected to flow cytometry on a FACScan® (Becton Dickinson & Co., Mountain View, CA).
CVF model oflung injury. Specific pathogen-free, adult (250-350 g), male Long-Evans rats were used. 20 U ofCVF/kg body wt together with an aliquot of 1251-BSA (0.5 ,iCi) were injected intravenously as a bolus infusion (28) . Animals were anesthetized with ketamine hydrochloride (100 mg/kg) (Parke Davis and Co., Morris Plains, NJ) and exsanguinated via the posterior vena cava 30 min after infusion of CVF. Negative control animals (receiving PBS, pH 7.4) were similarly treated but CVF was omitted in the intravenously infused PBS. The lung vasculature was then perfused through the right cardiac ventricle with 10 ml ofPBS. The lungs were removed and the amount ofradioactivity remaining within the tissue was assessed with a gamma scintillation counter. Lung damage was defined by the increased lung vascular permeability (as determined by the ratio of'251I-BSA radioactivity present within lung tissue to the amount of radioactivity present in 1.0 ml of venous blood obtained at the time of death) and by hemorrhage (5'Cr-red blood cell radioactivity, as described below). Protection from lung injury was calculated using the following equation: protection (%) = 100 x I test value -PBS value positive value -PBS value Tissue myeloperoxidase activity. To assess the use of tissue myelo--peroxidase (MPO) activity as a measure of neutrophil influx, known numbers of glycogen-elicited rat peritoneal neutrophils were added to normal rat lungs, the tissue homogenized and extracted, and standard curves produced ( 15) . Lung samples were homogenized with a homogenizer (Polytron; Tekmar Co., Cincinnati, OH) (4 X 10 s at a setting of 4) using 6 ml of homogenization buffer (50 mM phosphate, pH 6.0) and subjected to centrifugation (3,000 g, 30 min) at 4VC. MPO activity in supernatants was assayed by measuring the change in absorbance (460 nm) resulting from decomposition of H202 in the presence of o-dianisidine ( 15 ) .
Morphological evaluation oflungs. Light microscopy and transmission electron microscopy were carried out on lungs of animals 20 min after intravenous infusion of CVF, using plastic-embedded tissues (15) .
Immunoperoxidase analysis of lung. At the times indicated after infusion ofCVF and killing ofrats, lungs were inflated with warm OCT and snap-frozen in liquid nitrogen. Frozen sections of lung were obtained and mounted on poly-L-lysine-coated glass slides. The slides were then incubated with PB1.3 antibody (1.0 ng/ml) for 45 min at 250C, washed with PBS, and reacted with the biotin/avidin-peroxidase system as recently described ( 15) . Tissue sections were then counterstained with hematoxylin and permanently mounted with coverslips.
Results
In vitro characterization ofanti-P-selectin. For the in vivo studies, the two murine monoclonal antibodies (PB1.3 and PNB 1.6) to human P-selectin were used. Both antibodies were of the IgG, isotype and each reacted in the ELISA assay with human recombinant P-selectin and purified P-selectin, as well as with P-selectin on thrombin-activated platelets. In contrast, neither antibody reacted with recombinant E-or L-selectin (data not shown). As shown in Fig. 1 (left panel, B and C), immunoblotting revealed that both monoclonal antibodies recognized a single protein from human platelets with a molecular mass of 140 kD, as previously described for P-selectin (25) (26) (27) . One of the antibodies, PB 1.3 (anti-P-selectin/blocking IgG1, clone 352, lane C) blocked the P-selectin-mediated adhesion of human platelets (activated by thrombin) to human neutrophils, while the second antibody, PNB1.6 (anti-P-selectin/ nonblocking/IgG , clone P6H6), did not (Fig. 1, right panel) . Of particular importance for this study, PB1.3 also inhibited adhesion to human neutrophils ofthrombin-activated rat platelets (Fig. 1, right panel) and rabbit platelets (not shown). These data suggested that PB1.3 recognizes a conserved P-selectin epitope and that the antibody might be useful in the analysis of P-selectin function in animal models of inflammatory injury. PB 1.3 was demonstrated to react with thrombin-activated but not with unstimulated rat platelets, as shown in Fig. 2 . In both A (nonactivated platelets) and B (thrombin-activated platelets), the platelets were treated in the absence of antibody (none) or in the presence of an unrelated mouse IgG, isotopematched control antibody, or with PB 1.3 anti-P-selectin. The horizontal axis is a logarithmic scale of fluorescence (two divisions being equal to one log unit) while the vertical axis represents linear cell count. Nonactivated platelets showed little if any fluorescence (Fig. 2 A) while thrombin-activated platelets showed greatly increased fluorescence after incubation with PB 1.3, whereas activated platelets treated with the isotypematched control antibody or with buffer showed much less fluorescence intensity. In data not shown, neutrophils isolated from fresh rat blood failed to react with PB 1.3, as assessed in flow cytometry.
In vivo protective effects ofanti-P-human-selectin in CVFinduced lung injury. For . Fluid phase assay for P-selectin mediated adhesion of thrombin-activated platelets to human neutrophils. As indicated, PNB1.6 failed to inhibit binding of either human or rat activated platelets to human neutrophils, while PB1.3 inhibited adhesion of both human and rat platelets to neutrophils, with maximal inhibition by PB 1.3 at 0.1 Atg/ml and 10 ,g/ml, respectively (data not shown).
body wt were infused intravenously into 300-g adult male Long-Evans rats. This resulted in rapid intrapulmonary, intravascular sequestration ofblood neutrophils, with resulting damage ofinterstitial capillary endothelial cells at points ofphysical contact of endothelial cells and neutrophils (28) . When used, clones PBl.3 and PNB1.6 murine monoclonal antibodies to human P-selectin were infused intravenously in varying amounts (as indicated) together with CVF, in total vol of 0.5 ml. Negative control animals received 0.5 ml intravenous infusion of PBS. In all cases the infusion material also contained trace amounts of 125I-bovine serum albumin and homologous (Fig. 4) , consistent with the inability of this antibody to protect against CVF-induced lung injury (Fig. 3) . The protective effects ofthe blocking anti-P-selectin, PB Figure 4 . Lung MPO content in animals receiving an intravenous injection of CVF with PBS, 200 ,g PNB1.6, or 100-400 Mg PB1.3, followed by killing at 30 min. Lungs were homogenized and sonicated as described elsewhere ( 15) . MPO activity in supernatant fluids was measured by the change (per minute) in optical density (at 460 nm) resulting from the decomposition of H202 in the presence of o-dianisidine. The mean negative control MPO value of 0.08±0.01 in PBSinfused rats rose to 0.47±0.02 in the CVF-PBS infused rats. In animals also treated with 200 jig PNB 1.6, the MPO value was 0.49±0.03. In CVF-injected animals also treated with PB 1.3, there was a dosedependent reduction (26-50%) in lung content of MPO. One-way analysis of variance of these data revealed P < .001. These P values were determined by comparisons of each group to the positive control group (CVF in PBS). Percent reduction was calculated after first subtracting the background negative control value from all values of CVF-injected animals. (For each group, n = 5).
P-selectin and Lung Injury 1603 injury is concordant with its inability to block P-selectin-mediated adhesion of activated platelets to neutrophils (as described above). In the CVF model of lung injury the role of platelets in intravascular aggregation of neutrophils is unclear. The transmission electron micrographs do not provide evidence for the physical presence of platelets which might act as "bridging" for neutrophil adhesiveness via P-selectin. Whether platelets are involved in the intravascular aggregation ofneutrophils is not known. This raises the possibility that, via P-selectin, platelets activated by complement-generated anaphylatoxins may participate in the formation ofneutrophil aggregates in vivo. Again, the role ofplatelets in the pathogenesis ofCVF-induced lung injury cannot be determined at present.
Since anti-human P-selectin did not prevent the full extent of pulmonary vascular injury after infusion ofCVF, it is possible that other constitutively expressed adhesion-promoting molecules could also be functioning to promote adhesion between endothelial cells and neutrophils. These could include endothelial ICAM-l and the neutrophil #2 integrins. The mediator(s) responsible for the upregulation ofP-selectin on pulmonary vascular endothelial cells in the lung CVF model of lung injury has (have) not been identified, although it is known in this model that the levels of plasma histamine rise > 20-fold within 5 min after infusion of CVF (33) . Histamine is a welldocumented inducer of P-selectin expression on the surfaces of endothelial cells (24) , and the time course ofP-selectin expression (Fig. 5 ) would be consistent with the time course for the rise in plasma histamine after the infusion of CVF (33) . The data in this study provide evidence for the role of a rat P-selectin-like material in the acute inflammatory response. P-selectin has been shown to recognize a carbohydrate ligand, sialylated Lewisx, found on neutrophil glycoproteins and glycolipids (5, 6, 34) . Thus, it is likely that P-selectin interaction with glycoprotein (or glycolipid) ligands plays an important role in initiation of the acute inflammatory response. Studies are in progress to define further the nature of the rat epitope that is reactive with anti-human P-selectin.
